Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Long-term pharmacological augmentation is central to care for treatment-resistant depression, yet until recently no adequately powered trials have examined it. With three such studies now published, we highlight the hope they offer for improving outcomes in this underserved population while highlighting caution in interpreting their collective findings without careful consideration of methodology and clinical context. We consider these issues and their implications for guiding more personalised treatment decisions aimed at sustained benefit in routine practice.

More information Original publication

DOI

10.1192/bjp.2026.10673

Type

Journal article

Publication Date

2026-05-19T00:00:00+00:00

Pages

1 - 2

Total pages

1

Keywords

Augmentation, ketamine, lithium, quetiapine, treatment-resistant depression